News – Page 3 – AKL Therapeutics

MHRA awards Innovation Passport for APPA in Osteoarthritis

Following consideration by MHRA, NICE, and SMC, the Innovative Licensing and Access Pathway Steering Group has informed AKL that the innovative medicine designation, the Innovation Passport, has been awarded for APPA in the treatment of osteoarthritis. The Innovation Passport is the entry point to the Innovative Licensing and Access Pathway (ILAP) designed to accelerate the […]

APPA Phase II human study completes ahead of schedule

Despite Covid, the Phase II 150-patient placebo-controlled Human Efficacy Study of APPA in osteoarthritis of the knee has completed patient recruitment a month ahead of schedule and the last patient to enter the study completed their treatment on 16th April.

APPA reduces senescence & reactive oxygen species production

New data presented at the European League against Rheumatism (EULAR) demonstrates that APPA reduces the number of senescent chondrocytes, and inhibits ROS production in human articular chondrocytes. Today AKL unveils new data at the Virtual European Congress of Rheumatology (EULAR) 2021 (June 2-5). Findings from the study indicate our investigational oral osteoarthritis (OA) drug APPA […]

New studies suggests APPA protects against joint damage

Today sees the unveiling of new data at the Osteoarthritis Research Society International (OARSI) Virtual World Congress (April 29 – May 1) indicating investigational oral osteoarthritis (OA) drug APPA can modulate cellular function, reduce inflammation and inhibit bone resorption associated with joint degradation caused by the disease. Read full press release. Biological effect of APPA […]

Personalised Medicine & Disease Modification in OA

In this article we discuss the challenges in demonstrating disease modification in OA, illustrate this with examples of recently published clinical trials, and describe the current status of APPA, a novel, patented potential Disease Modifying Osteoarthritic Drug (DMOAD).

How close are disease‐modifying drugs for OA?

Progress in the development of disease‐modifying drugs for osteoarthritis has been hampered by a lack of understanding of the pathogenesis of the disease and how it differs from rheumatoid arthritis. However, more recent research in this field has identified several promising therapeutic targets. The symptoms of osteoarthritis, the most common joint disorder, typically emerge at […]